Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry
Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Da...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2011-08, Vol.87 (2), p.157-168 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 168 |
|---|---|
| container_issue | 2 |
| container_start_page | 157 |
| container_title | European journal of haematology |
| container_volume | 87 |
| creator | Faber, Edgar Mužík, Jan Koza, Vladimír Demečková, Eva Voglová, Jaroslava Demitrovičová, Ĺudmila Chudej, Juraj Markuljak, Imrich Cmunt, Eduard Kozák, Tomáš Tóthová, Elena Jarošová, Marie Dušek, Ladislav Indrák, Karel |
| description | Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Data reporting was retrospective in 2000–2004 and prospective from 2005 on. A total of 661 patients [301 women and 360 men; median age 51 (range, 15–83)] with Ph + CML were registered. The median follow‐up was 46.1 months (0–122.2). Results: Most patients were treated with first‐ (379; 57.3%) or second‐line (193; 29.2%) imatinib; some of the patients underwent allogeneic hematopoietic stem cell transplantation (AHSCT) (83; 12.6%), but 6.1% were treated with other modalities [40 patients; median age 66 (range, 32–83)]. The probability of overall survival (OS) at 5 years, according to Kaplan and Meier, was 88.9%, 77.5% and 68.7% for chronic‐phase patients treated with first‐line imatinib, second‐line imatinib and first‐line AHSCT, respectively, but only 25.2% for patients receiving other modalities. The OS was dependent on the disease phase and Sokal, Hasford and European group for blood and marrow transplantation (EBMT) risk scores (P |
| doi_str_mv | 10.1111/j.1600-0609.2011.01637.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_887502781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>887502781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3577-d6b5a915a6aee18fb7c7f85f8938be89c648a067afc2f8f0edea709211498f6b3</originalsourceid><addsrcrecordid>eNpFkc1y0zAUhT0MDE0Lr8Box8pG8p_kBYsQQlMmlBkoAzuNLF_VSmzLSHaT9CF5JuSkBG2kufd8597RCQJEcET8ebeJSI5xiHNcRDEmJMIkT2i0fxbMzo3nwQwXOA7TNCUXwaVzG4xxXBD6MriISZZkXjkL_txZEEML3YCMQtJ0DuQ46AdAvRi0Lzu000ONZG1NpyVqD9AYXaEGxq2AVgukOzTU4FHTg_VMd4-k5yw4pKxpj83FI8gafYN-LBtvIrrqWN7VpoFp7vfGPIitNxNqAItivykKkUAWemOH_z696cfGzzBdWAoHFVrMvyzXN3Nvfa_dYA-vghdKNA5eP91XwY9Py7vFKlx_vb5ZzNehTDJKwyovM1GQTOQCgDBVUkkVyxQrElYCK2SeMoFzKpSMFVMYKhAUFzEhacFUXiZXwduTb2_N7xHcwFvtJDSN6MCMjjNGMxxTRrzyzZNyLFuoeG91K-yB_4vAC96fBDvdwOHcJ5hPUfMNnxLlU6J8ipofo-Z7vvy8ml6eD0-8_wDYn3lhtzynCc34z9trTlcfP9wuVmv-K_kLBSOu_A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>887502781</pqid></control><display><type>article</type><title>Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Faber, Edgar ; Mužík, Jan ; Koza, Vladimír ; Demečková, Eva ; Voglová, Jaroslava ; Demitrovičová, Ĺudmila ; Chudej, Juraj ; Markuljak, Imrich ; Cmunt, Eduard ; Kozák, Tomáš ; Tóthová, Elena ; Jarošová, Marie ; Dušek, Ladislav ; Indrák, Karel</creator><creatorcontrib>Faber, Edgar ; Mužík, Jan ; Koza, Vladimír ; Demečková, Eva ; Voglová, Jaroslava ; Demitrovičová, Ĺudmila ; Chudej, Juraj ; Markuljak, Imrich ; Cmunt, Eduard ; Kozák, Tomáš ; Tóthová, Elena ; Jarošová, Marie ; Dušek, Ladislav ; Indrák, Karel</creatorcontrib><description>Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Data reporting was retrospective in 2000–2004 and prospective from 2005 on. A total of 661 patients [301 women and 360 men; median age 51 (range, 15–83)] with Ph + CML were registered. The median follow‐up was 46.1 months (0–122.2). Results: Most patients were treated with first‐ (379; 57.3%) or second‐line (193; 29.2%) imatinib; some of the patients underwent allogeneic hematopoietic stem cell transplantation (AHSCT) (83; 12.6%), but 6.1% were treated with other modalities [40 patients; median age 66 (range, 32–83)]. The probability of overall survival (OS) at 5 years, according to Kaplan and Meier, was 88.9%, 77.5% and 68.7% for chronic‐phase patients treated with first‐line imatinib, second‐line imatinib and first‐line AHSCT, respectively, but only 25.2% for patients receiving other modalities. The OS was dependent on the disease phase and Sokal, Hasford and European group for blood and marrow transplantation (EBMT) risk scores (P < 0.001; each). Only 46.2% of deaths in patients treated with other modalities were attributable to CML. Elderly patients over 65 years achieved similar response rates and progression‐free survival to the younger ones. There was a trend for inferior results of AHSCT performed after the failure of imatinib (P = 0.075), probably as a result of differences in EBMT risk scores (P < 0.001). Conclusions: The ability to achieve results comparable to those of previous clinical studies in our CML cohort was influenced by centralised care. Decisions not to initiate imatinib or to delay AHSCT may have a negative impact on OS, but comorbidities may limit the treatment potential of imatinib in the elderly.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/j.1600-0609.2011.01637.x</identifier><identifier>PMID: 21535160</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; allogeneic stem cell transplantation ; Antineoplastic Agents - therapeutic use ; Benzamides ; chronic myeloid leukaemia ; Czech Republic - epidemiology ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; imatinib ; Imatinib Mesylate ; interferon ; Kaplan-Meier Estimate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy ; Male ; Middle Aged ; Piperazines - therapeutic use ; Prospective Studies ; Pyrimidines - therapeutic use ; Registries ; registry ; Retrospective Studies ; Slovakia - epidemiology ; Transplantation, Homologous ; tyrosine kinase inhibitors ; Young Adult</subject><ispartof>European journal of haematology, 2011-08, Vol.87 (2), p.157-168</ispartof><rights>2011 John Wiley & Sons A/S</rights><rights>2011 John Wiley & Sons A/S.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3577-d6b5a915a6aee18fb7c7f85f8938be89c648a067afc2f8f0edea709211498f6b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-0609.2011.01637.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-0609.2011.01637.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21535160$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Faber, Edgar</creatorcontrib><creatorcontrib>Mužík, Jan</creatorcontrib><creatorcontrib>Koza, Vladimír</creatorcontrib><creatorcontrib>Demečková, Eva</creatorcontrib><creatorcontrib>Voglová, Jaroslava</creatorcontrib><creatorcontrib>Demitrovičová, Ĺudmila</creatorcontrib><creatorcontrib>Chudej, Juraj</creatorcontrib><creatorcontrib>Markuljak, Imrich</creatorcontrib><creatorcontrib>Cmunt, Eduard</creatorcontrib><creatorcontrib>Kozák, Tomáš</creatorcontrib><creatorcontrib>Tóthová, Elena</creatorcontrib><creatorcontrib>Jarošová, Marie</creatorcontrib><creatorcontrib>Dušek, Ladislav</creatorcontrib><creatorcontrib>Indrák, Karel</creatorcontrib><title>Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Data reporting was retrospective in 2000–2004 and prospective from 2005 on. A total of 661 patients [301 women and 360 men; median age 51 (range, 15–83)] with Ph + CML were registered. The median follow‐up was 46.1 months (0–122.2). Results: Most patients were treated with first‐ (379; 57.3%) or second‐line (193; 29.2%) imatinib; some of the patients underwent allogeneic hematopoietic stem cell transplantation (AHSCT) (83; 12.6%), but 6.1% were treated with other modalities [40 patients; median age 66 (range, 32–83)]. The probability of overall survival (OS) at 5 years, according to Kaplan and Meier, was 88.9%, 77.5% and 68.7% for chronic‐phase patients treated with first‐line imatinib, second‐line imatinib and first‐line AHSCT, respectively, but only 25.2% for patients receiving other modalities. The OS was dependent on the disease phase and Sokal, Hasford and European group for blood and marrow transplantation (EBMT) risk scores (P < 0.001; each). Only 46.2% of deaths in patients treated with other modalities were attributable to CML. Elderly patients over 65 years achieved similar response rates and progression‐free survival to the younger ones. There was a trend for inferior results of AHSCT performed after the failure of imatinib (P = 0.075), probably as a result of differences in EBMT risk scores (P < 0.001). Conclusions: The ability to achieve results comparable to those of previous clinical studies in our CML cohort was influenced by centralised care. Decisions not to initiate imatinib or to delay AHSCT may have a negative impact on OS, but comorbidities may limit the treatment potential of imatinib in the elderly.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>allogeneic stem cell transplantation</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>chronic myeloid leukaemia</subject><subject>Czech Republic - epidemiology</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>imatinib</subject><subject>Imatinib Mesylate</subject><subject>interferon</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Piperazines - therapeutic use</subject><subject>Prospective Studies</subject><subject>Pyrimidines - therapeutic use</subject><subject>Registries</subject><subject>registry</subject><subject>Retrospective Studies</subject><subject>Slovakia - epidemiology</subject><subject>Transplantation, Homologous</subject><subject>tyrosine kinase inhibitors</subject><subject>Young Adult</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc1y0zAUhT0MDE0Lr8Box8pG8p_kBYsQQlMmlBkoAzuNLF_VSmzLSHaT9CF5JuSkBG2kufd8597RCQJEcET8ebeJSI5xiHNcRDEmJMIkT2i0fxbMzo3nwQwXOA7TNCUXwaVzG4xxXBD6MriISZZkXjkL_txZEEML3YCMQtJ0DuQ46AdAvRi0Lzu000ONZG1NpyVqD9AYXaEGxq2AVgukOzTU4FHTg_VMd4-k5yw4pKxpj83FI8gafYN-LBtvIrrqWN7VpoFp7vfGPIitNxNqAItivykKkUAWemOH_z696cfGzzBdWAoHFVrMvyzXN3Nvfa_dYA-vghdKNA5eP91XwY9Py7vFKlx_vb5ZzNehTDJKwyovM1GQTOQCgDBVUkkVyxQrElYCK2SeMoFzKpSMFVMYKhAUFzEhacFUXiZXwduTb2_N7xHcwFvtJDSN6MCMjjNGMxxTRrzyzZNyLFuoeG91K-yB_4vAC96fBDvdwOHcJ5hPUfMNnxLlU6J8ipofo-Z7vvy8ml6eD0-8_wDYn3lhtzynCc34z9trTlcfP9wuVmv-K_kLBSOu_A</recordid><startdate>201108</startdate><enddate>201108</enddate><creator>Faber, Edgar</creator><creator>Mužík, Jan</creator><creator>Koza, Vladimír</creator><creator>Demečková, Eva</creator><creator>Voglová, Jaroslava</creator><creator>Demitrovičová, Ĺudmila</creator><creator>Chudej, Juraj</creator><creator>Markuljak, Imrich</creator><creator>Cmunt, Eduard</creator><creator>Kozák, Tomáš</creator><creator>Tóthová, Elena</creator><creator>Jarošová, Marie</creator><creator>Dušek, Ladislav</creator><creator>Indrák, Karel</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201108</creationdate><title>Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry</title><author>Faber, Edgar ; Mužík, Jan ; Koza, Vladimír ; Demečková, Eva ; Voglová, Jaroslava ; Demitrovičová, Ĺudmila ; Chudej, Juraj ; Markuljak, Imrich ; Cmunt, Eduard ; Kozák, Tomáš ; Tóthová, Elena ; Jarošová, Marie ; Dušek, Ladislav ; Indrák, Karel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3577-d6b5a915a6aee18fb7c7f85f8938be89c648a067afc2f8f0edea709211498f6b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>allogeneic stem cell transplantation</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>chronic myeloid leukaemia</topic><topic>Czech Republic - epidemiology</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>imatinib</topic><topic>Imatinib Mesylate</topic><topic>interferon</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Piperazines - therapeutic use</topic><topic>Prospective Studies</topic><topic>Pyrimidines - therapeutic use</topic><topic>Registries</topic><topic>registry</topic><topic>Retrospective Studies</topic><topic>Slovakia - epidemiology</topic><topic>Transplantation, Homologous</topic><topic>tyrosine kinase inhibitors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Faber, Edgar</creatorcontrib><creatorcontrib>Mužík, Jan</creatorcontrib><creatorcontrib>Koza, Vladimír</creatorcontrib><creatorcontrib>Demečková, Eva</creatorcontrib><creatorcontrib>Voglová, Jaroslava</creatorcontrib><creatorcontrib>Demitrovičová, Ĺudmila</creatorcontrib><creatorcontrib>Chudej, Juraj</creatorcontrib><creatorcontrib>Markuljak, Imrich</creatorcontrib><creatorcontrib>Cmunt, Eduard</creatorcontrib><creatorcontrib>Kozák, Tomáš</creatorcontrib><creatorcontrib>Tóthová, Elena</creatorcontrib><creatorcontrib>Jarošová, Marie</creatorcontrib><creatorcontrib>Dušek, Ladislav</creatorcontrib><creatorcontrib>Indrák, Karel</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Faber, Edgar</au><au>Mužík, Jan</au><au>Koza, Vladimír</au><au>Demečková, Eva</au><au>Voglová, Jaroslava</au><au>Demitrovičová, Ĺudmila</au><au>Chudej, Juraj</au><au>Markuljak, Imrich</au><au>Cmunt, Eduard</au><au>Kozák, Tomáš</au><au>Tóthová, Elena</au><au>Jarošová, Marie</au><au>Dušek, Ladislav</au><au>Indrák, Karel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2011-08</date><risdate>2011</risdate><volume>87</volume><issue>2</issue><spage>157</spage><epage>168</epage><pages>157-168</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Background: Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres during 2000–2008. Patients and methods: Data reporting was retrospective in 2000–2004 and prospective from 2005 on. A total of 661 patients [301 women and 360 men; median age 51 (range, 15–83)] with Ph + CML were registered. The median follow‐up was 46.1 months (0–122.2). Results: Most patients were treated with first‐ (379; 57.3%) or second‐line (193; 29.2%) imatinib; some of the patients underwent allogeneic hematopoietic stem cell transplantation (AHSCT) (83; 12.6%), but 6.1% were treated with other modalities [40 patients; median age 66 (range, 32–83)]. The probability of overall survival (OS) at 5 years, according to Kaplan and Meier, was 88.9%, 77.5% and 68.7% for chronic‐phase patients treated with first‐line imatinib, second‐line imatinib and first‐line AHSCT, respectively, but only 25.2% for patients receiving other modalities. The OS was dependent on the disease phase and Sokal, Hasford and European group for blood and marrow transplantation (EBMT) risk scores (P < 0.001; each). Only 46.2% of deaths in patients treated with other modalities were attributable to CML. Elderly patients over 65 years achieved similar response rates and progression‐free survival to the younger ones. There was a trend for inferior results of AHSCT performed after the failure of imatinib (P = 0.075), probably as a result of differences in EBMT risk scores (P < 0.001). Conclusions: The ability to achieve results comparable to those of previous clinical studies in our CML cohort was influenced by centralised care. Decisions not to initiate imatinib or to delay AHSCT may have a negative impact on OS, but comorbidities may limit the treatment potential of imatinib in the elderly.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21535160</pmid><doi>10.1111/j.1600-0609.2011.01637.x</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2011-08, Vol.87 (2), p.157-168 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_887502781 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over allogeneic stem cell transplantation Antineoplastic Agents - therapeutic use Benzamides chronic myeloid leukaemia Czech Republic - epidemiology Disease-Free Survival Female Hematopoietic Stem Cell Transplantation Humans imatinib Imatinib Mesylate interferon Kaplan-Meier Estimate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Male Middle Aged Piperazines - therapeutic use Prospective Studies Pyrimidines - therapeutic use Registries registry Retrospective Studies Slovakia - epidemiology Transplantation, Homologous tyrosine kinase inhibitors Young Adult |
| title | Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A25%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20consecutive%20patients%20with%20chronic%20myeloid%20leukaemia%20in%20the%20cooperating%20centres%20from%20the%20Czech%20Republic%20and%20the%20whole%20of%20Slovakia%20after%202000%20-%20a%20report%20from%20the%20population-based%20CAMELIA%20Registry&rft.jtitle=European%20journal%20of%20haematology&rft.au=Faber,%20Edgar&rft.date=2011-08&rft.volume=87&rft.issue=2&rft.spage=157&rft.epage=168&rft.pages=157-168&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/j.1600-0609.2011.01637.x&rft_dat=%3Cproquest_pubme%3E887502781%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=887502781&rft_id=info:pmid/21535160&rfr_iscdi=true |